{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:01:10Z","timestamp":1777878070524,"version":"3.51.4"},"reference-count":16,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NCI Grant number P30 CA91842."],"award-info":[{"award-number":["NCI Grant number P30 CA91842."]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Rare Tumors"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>\n                    Historically, administration of dacarbazine to sarcoma patients was limited by frequent treat-ment-related nausea\/vomiting and neutropenia. These toxicities are now largely preventable with contemporary antiemetics and growth factor support. In this single-arm, phase II study, dacarbazine 850 mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    was given on day 1 of each 3-week cycle until disease progression or intolerance with prophylactic serotonin-3 receptor, neurokinin-1 antagonists, corticosteroids, and pegfilgrastim. Coprimary endpoints included clinical benefit rate (CBR), and any grade of nausea\/vomiting and\/or grade 3\u20134 neutropenia. With a sample size of 80 patients, &gt;24 patients with clinical benefit would indicate that the CBR exceeds the historical (&lt;20%) [Power 0.80; alpha 0.05]. In addition, we hypothesized that the rates of nausea\/vomiting would be 27% and grade 3\u20134 neutropenia would be 1% (historical: 90% and 36%, respectively) [power 0.95; alpha 0.05]. The CBR was 30% (24 patients: PR-2 and stable-22). The rate of nausea\/vomiting was 37.5% (31 patients) and grades 3\u20134 neutropenia was 10% (8 patients). Median time-to-progression was 8.1 weeks (95% CI 8\u20139.7) and median overall survival was 35.8 weeks (95% CI 26.2\u201355.4). PET scans demonstrated no association with response. Modern prophylactic anti-emetics and pegfilgrastim given with dacarbazine reduced the rates of treatment related nausea\/vomiting and serious neutropenia.\n                  <\/jats:p>","DOI":"10.1177\/20363613211052498","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T04:06:15Z","timestamp":1633838775000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Phase II study of dacarbazine given with modern prophylactic anti-emetics and growth factor support to patients with metastatic, resistant soft tissue, and bone sarcoma"],"prefix":"10.1177","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4572-6668","authenticated-orcid":false,"given":"Brian A","family":"Van Tine","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA"},{"name":"Division of Pediatric Hematology and Oncology, St. Louis Children\u2019s Hospital, St. Louis, MO, USA"},{"name":"Siteman Cancer Center, St. Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mia C","family":"Weiss","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA"},{"name":"Siteman Cancer Center, St. Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1719-0771","authenticated-orcid":false,"given":"Angela C","family":"Hirbe","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA"},{"name":"Division of Pediatric Hematology and Oncology, St. Louis Children\u2019s Hospital, St. Louis, MO, USA"},{"name":"Siteman Cancer Center, St. Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J","family":"Oppelt","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA"},{"name":"Siteman Cancer Center, St. Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Abaricia","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Trinkaus","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Washington University in St. Louis, St. Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingqin","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Washington University in St. Louis, St. Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shellie","family":"Berry","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler","family":"Ruff","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl","family":"Callahan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqui","family":"Toensikoetter","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Ley","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn J","family":"Siegel","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center, St. Louis, MO, USA"},{"name":"Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farrokh","family":"Dehdashti","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center, St. Louis, MO, USA"},{"name":"Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry A","family":"Siegel","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center, St. Louis, MO, USA"},{"name":"Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas R","family":"Adkins","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA"},{"name":"Siteman Cancer Center, St. Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"bibr1-20363613211052498","unstructured":"Cancer Facts & Figures [Webpage]. Key statistics for soft tissue sarcomas, https:\/\/www.cancer.org\/cancer\/soft-tissue-sarcoma\/about\/key-statistics.html#references (2020, accessed 16 August 2020)."},{"key":"bibr2-20363613211052498","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(99)00240-3"},{"key":"bibr3-20363613211052498","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008279426654"},{"key":"bibr4-20363613211052498","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.4117"},{"key":"bibr5-20363613211052498","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.10545"},{"key":"bibr6-20363613211052498","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds070"},{"issue":"2","key":"bibr7-20363613211052498","first-page":"199","volume":"60","author":"Gottlieb JA","year":"1976","journal-title":"Cancer Treat Rep"},{"key":"bibr8-20363613211052498","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197212)30:6<1632::AID-CNCR2820300632>3.0.CO;2-S"},{"key":"bibr9-20363613211052498","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-007-9086-z"},{"key":"bibr10-20363613211052498","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4734"},{"key":"bibr11-20363613211052498","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.18_suppl.lba10502"},{"key":"bibr12-20363613211052498","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"bibr13-20363613211052498","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(99)00229-4"},{"key":"bibr14-20363613211052498","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.07.002"},{"key":"bibr15-20363613211052498","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpet.2018.08.012"},{"key":"bibr16-20363613211052498","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2017.1329"}],"container-title":["Rare Tumors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20363613211052498","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20363613211052498","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20363613211052498","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:10:58Z","timestamp":1777590658000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20363613211052498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":16,"alternative-id":["10.1177\/20363613211052498"],"URL":"https:\/\/doi.org\/10.1177\/20363613211052498","relation":{},"ISSN":["2036-3613","2036-3613"],"issn-type":[{"value":"2036-3613","type":"print"},{"value":"2036-3613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"20363613211052498"}}